But Sparer said more people with insurance will be able to afford tests and treatments they had put off or avoided altogether. And those over 65 will grow from about 40 million in 2010 to more than 70 million by 2030, increasing the number of people who need devices.
News releases from August state that diabetes medical device manufacturers expect the global market to grow from $17.7 billion in 2011 to $25.3 billion in 2018, according to GBI Research.
Johnson & Johnson, which released a statement saying it supported the law after the Supreme Court decision, bought Synthes in June for $19.7 billion.
In announcing the deal, Johnson & Johnson said it expected the company to do well because the United States has an aging population, increasing rates of obesity and associated joint disease, patients' desire to remain active, new markets and a move toward earlier intervention.